Nifuroxazide
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Nifuroxazide is an antibiotic indicated in the treatment of susceptible gastrointestinal infections.
- Generic Name
- Nifuroxazide
- DrugBank Accession Number
- DB13855
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 275.22
Monoisotopic: 275.054220402 - Chemical Formula
- C12H9N3O5
- Synonyms
- Nifuroxazide
- External IDs
- RC-27109
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute diarrhoea •••••••••••• •••••••• ••••••••••• ••••• Used in combination to treat Amoebiasis Combination Product in combination with: Metronidazole (DB00916) •••••••••••• ••••••••••• ••••••• •••• •••••• Used in combination to treat Amoebiasis Combination Product in combination with: Metronidazole benzoate (DB15759) •••••••••••• •••••••• •••••••••• Used in combination to treat Amoebiasis Combination Product in combination with: Metronidazole (DB00916) •••••••••••• •••••••• •••••••••• Used in combination to treat Amoebic liver abscess Combination Product in combination with: Metronidazole (DB00916) •••••••••••• ••••••••••• ••••••• •••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AMEBICOL® Nifuroxazide (200 mg) + Metronidazole (300 mg) Capsule, coated Oral BIOQUIMICO PHARMAS.A. 2017-05-22 Not applicable Colombia DIARSET NX- M SUSPENSION Nifuroxazide (4 g) + Metronidazole benzoate (5 g) Suspension Oral ARBOFARMA S.A.S. 2007-07-30 Not applicable Colombia DIARSET NX® M CAPSULAS Nifuroxazide (200 mg) + Metronidazole (600 mg) Capsule, coated Oral COLOMPACK S.A. 2014-01-10 Not applicable Colombia FUROTIL®CAPSULAS Nifuroxazide (200 mg) + Metronidazole (600 mg) Capsule, coated Oral COLOMPACK S.A. 2021-09-16 Not applicable Colombia INVERPAR® SUSPENSIÓN Nifuroxazide (4 g) + Metronidazole (8 g) Suspension Oral COLOMPACK S.A. 2009-08-21 2020-04-15 Colombia
Categories
- ATC Codes
- A07AX03 — Nifuroxazide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzoic acids and derivatives. These are organic compounds containing a carboxylic acid substituent attached to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Benzoic acids and derivatives
- Alternative Parents
- Nitrofurans / Nitroaromatic compounds / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic oxoazanium compounds / Carboxylic acids and derivatives / Organopnictogen compounds show 5 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 2-nitrofuran / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Benzoic acid or derivatives / Benzoyl / C-nitro compound / Carboxylic acid derivative / Furan / Heteroaromatic compound show 16 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PM5LI0P38J
- CAS number
- 965-52-6
- InChI Key
- YCWSUKQGVSGXJO-NTUHNPAUSA-N
- InChI
- InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+
- IUPAC Name
- 4-hydroxy-N'-[(1E)-(5-nitrofuran-2-yl)methylidene]benzohydrazide
- SMILES
- OC1=CC=C(C=C1)C(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O
References
- General References
- INVIMA: Acta 15 (21 and 22 July 2015) [Link]
- External Links
- ChemSpider
- 4495115
- BindingDB
- 50396177
- 31782
- ChEBI
- 135136
- ChEMBL
- CHEMBL244888
- ZINC
- ZINC000000001808
- Wikipedia
- Nifuroxazide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Hepatic Encephalopathy (HE) 1 2, 3 Recruiting Treatment Inflammatory Bowel Diseases (IBD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 200.000 mg Suspension Oral 4.000 g Suspension Oral 4.400 g Suspension Oral Suspension Oral 4.4 g Suspension Oral 4.483 g Tablet Oral Suspension Oral 60 ml Suspension Oral 4 g Tablet Oral 200 mg Capsule Oral 200 MG Capsule, coated Oral 200 mg Capsule Oral 100 mg Suspension Oral 200 mg Suspension Oral 4.40 g Capsule Oral Tablet, coated Oral Suspension Oral Suspension Oral 200 mg/5ml Capsule, coated Oral Capsule, coated Oral 600 mg Capsule, liquid filled Oral Tablet, film coated Oral Syrup Oral Capsule Oral 400.000 mg Suspension Oral 218 mg/5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.105 mg/mL ALOGPS logP 2.59 ALOGPS logP 1.75 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 8.33 Chemaxon pKa (Strongest Basic) -1.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 117.97 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 68.18 m3·mol-1 Chemaxon Polarizability 26 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-00di-1920000000-6aa7111b577261e72557 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 152.87921 predictedDeepCCS 1.0 (2019) [M+H]+ 155.23723 predictedDeepCCS 1.0 (2019) [M+Na]+ 162.33952 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23